Using an Antagonist of Chimeric Receptor Antigen T Cell Therapy to Prevent Cytokine Storm in COVID-19: A Hypothesis

Ngokwe Zilefac Brian, Fokam Tamoh Stive, Bienvenue NtepNtep David, Stephane Nokam Kamdem, Fon Cheboh Cho, Audrey Kouamou Tchiekou, Macbrain Elage Epie, Arthur Tamgnoue Guillaume
{"title":"Using an Antagonist of Chimeric Receptor Antigen T Cell Therapy to Prevent Cytokine Storm in COVID-19: A Hypothesis","authors":"Ngokwe Zilefac Brian, Fokam Tamoh Stive, Bienvenue NtepNtep David, Stephane Nokam Kamdem, Fon Cheboh Cho, Audrey Kouamou Tchiekou, Macbrain Elage Epie, Arthur Tamgnoue Guillaume","doi":"10.23937/2378-3672/1410068","DOIUrl":null,"url":null,"abstract":"SARS-COV-2 pandemic is almost 3-years-old and remains a case for concern. An overwhelming production of pro-inflammatory cytokines in the context of COVID-19, not only impairs viral clearance but also promotes paradoxically hyperinflammation including cytokine storm; an unfortunate event leading to organ failure following long term damage due to inflammation and even death. With the advent of new variants, the interaction between vaccinated and unvaccinated people and also the interaction between persons with different variants or between the healthy and the asymptomatic; all of these possibly leading to the formation of new variants. CAR T therapy has achieved remarkable clinical results treatment of relapsed/refractory B-cell-derived malignancies. CAR T and SARS-COV-2 share one thing in common; the cytokine storm even though the former is a treatment associated complication and the latter is an exaggerated host response. Hence, we propose using Immunopharmacology (which targets amongst others, pathologies in which inflammation is the main component), by using anti-CAR-engineered T to target the cytokine storm in COVID-19 with objective to help alleviate these symptoms or as a possible solution. Specifically, by using T lymphocytes as living drugs equipped with a CAR construct directed against TH2 or viral epitopes. We hope to curb the severe complications and the poor outcomes (mortalities) associated with this pathology.","PeriodicalId":92912,"journal":{"name":"International journal of immunology and immunotherapy","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of immunology and immunotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23937/2378-3672/1410068","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

SARS-COV-2 pandemic is almost 3-years-old and remains a case for concern. An overwhelming production of pro-inflammatory cytokines in the context of COVID-19, not only impairs viral clearance but also promotes paradoxically hyperinflammation including cytokine storm; an unfortunate event leading to organ failure following long term damage due to inflammation and even death. With the advent of new variants, the interaction between vaccinated and unvaccinated people and also the interaction between persons with different variants or between the healthy and the asymptomatic; all of these possibly leading to the formation of new variants. CAR T therapy has achieved remarkable clinical results treatment of relapsed/refractory B-cell-derived malignancies. CAR T and SARS-COV-2 share one thing in common; the cytokine storm even though the former is a treatment associated complication and the latter is an exaggerated host response. Hence, we propose using Immunopharmacology (which targets amongst others, pathologies in which inflammation is the main component), by using anti-CAR-engineered T to target the cytokine storm in COVID-19 with objective to help alleviate these symptoms or as a possible solution. Specifically, by using T lymphocytes as living drugs equipped with a CAR construct directed against TH2 or viral epitopes. We hope to curb the severe complications and the poor outcomes (mortalities) associated with this pathology.
使用嵌合受体抗原T细胞拮抗剂治疗COVID-19预防细胞因子风暴:一个假设
SARS-COV-2大流行已经近3年了,仍然是一个令人担忧的病例。在COVID-19背景下,促炎细胞因子的大量产生不仅会损害病毒清除,还会促进包括细胞因子风暴在内的矛盾的过度炎症;一种因炎症甚至死亡而导致器官衰竭的不幸事件。随着新变种的出现,接种疫苗的人和未接种疫苗的人之间的相互作用以及不同变种的人之间或健康人与无症状者之间的相互作用;所有这些都可能导致新的变种的形成。CAR - T疗法在治疗复发/难治性b细胞源性恶性肿瘤方面取得了显著的临床效果。CAR - T和SARS-COV-2有一个共同点;细胞因子风暴,尽管前者是治疗相关的并发症,后者是一种夸大的宿主反应。因此,我们建议使用免疫药理学(其中针对炎症为主要成分的病理),通过使用抗car工程T靶向COVID-19中的细胞因子风暴,目的是帮助缓解这些症状或作为可能的解决方案。具体来说,通过使用T淋巴细胞作为活的药物,配备了针对TH2或病毒表位的CAR结构。我们希望能够控制与这种病理相关的严重并发症和不良预后(死亡率)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信